Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

>2 yearsConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementStandard MedicinesInjectionGastroenterologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Pembrolizumab
Pembrolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-1.
Trastuzumab
Trastuzumab is a substance that targets HER2 proteins to treat certain HER2-positive breast and stomach cancers.
Trastuzumab Emtansine
Trastuzumab emtansine is a targeted cancer substance that binds HER2-positive cancer cells and delivers chemotherapy directly to kill them.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Klinikum St Marien Amberg
Studienzentrum
Amberg, Germany
Evangelisches Klinikum Bethel gGmbH
Klinik fuer Innere Medizin, Onkologie, Haematologie und Palliativmedizin
Bielefeld, Germany
Technische Universitaet Dresden
Medizinische Klinik und Poliklinik I
Dresden, Germany
Sponsor: Shanghai Henlius Biotech Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.